Utility of bolus somatostatin administration in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: A controlled, non-randomized study;Utilidad de la somatostatina administrada en bolo para prevenir la pancreatitis tras CPRE: Estudio controlado no aleatorizado

Gastroenterologia y Hepatologia

Volumn 29, Issue 4, 2006, Pages 231-236

  Vila, J J ^a   Jimenez F J ^a   Prieto, C ^a   Borobio, E ^a   Juanmartinena J F ^a   Borda, F ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SOMATOSTATIN;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS DUCT; TREATMENT OUTCOME; VATER PAPILLA;

EID: 33646260686     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13085969     Document Type: Article

References (28)

1. Huguet JM, Sempere J, Bort I, Canelles P, Rodríguez E, Dura AB, et al. Complications of endoscopic retrograde cholangiopancreatography in patients aged more than 90 years old. Gastroenterol Hepatol. 2005;28:263-6.
2. García-Cano J. Endoscopic retrograde cholangiopancreatography in patients aged. Gastroenterol Hepatol. 2005;28:509-10.
3. Sherman S, Lehman GA. ERCP -and endoscopic sphincterotomy- induced pancreatitis. Pancreas. 1991;6:350-67.
4. Sherman S, Earle D, Bucksot L, Baute P, Gottleib K, Lehman G, et al. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy (ES)-induced pancreatitis?: a final analysis of a randomized prospective study [resumen]. Gastrointest Endosc. 1996;43:AB413.
5. Madanick RD, O'Loughlin CJ, Barkin JS. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Dig Dis Sci. 2005;50:879-81.
6. Poon RT, Fan ST. Antisecretory agents for prevention of post-ERCP pancreatitis: rationale for use and clinical results. JOP. 2003;4:33-40.
7. Bordás JM, Toledo-Pimentel V, Llach J, Elena M, Mondelo F, Ginés A, et al. Effects of bolus somatostatin in preventing pancreatitis alter endoscopic pancreatography: results of a randomized study. Gastrointest Endosc. 1998;47:230-4.
8. Poon RT, Yeung C, Lo CM, Yuen WK, Liu CL, Fan ST. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc. 1999;49:593-8.
9. Andriulli A, Leandro G, Niro G, Mangia A, Festa V, Gambassi G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc. 2000;51:1-7.
10. Andriullli A, Clemente R, Solmi L, Terruzzi V, Suriani R, Sigillito A, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc. 2002;56:488-95.
11. Andriulli A, Solmi L, Loperfido S, Leo P, Festa V, Belmonte A, et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol. 2004;2:713-8.
12. Poon RT, Yeung C, Liu CL, Lam CM, Yuen WK, Lo CM, et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidente of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. Gut. 2003;52:1768-73.
13. Arvanitidis D, Anagnostopoulos GK, Giannopoulos D, Pantes A, Agaritsi R, Margantinis G, et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol. 2004;19:278-82.
14. Andriulli A, Caruso N, Quitadamo M, Forlano R, Leandro G, Spirito F, et al. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study. JOP. 2003;4:41-8.
15. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al. Endoscopic sphyncterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991;37:383-93.
16. Raju G. Prevention of post-ERCP pancreatitis: are there any pearls for sale? Gastroenterology. 2004;127:348-50.
17. Testoni PA. Why the incidence of post-ERCP pancreatitis varies considerably? Factors affecting the diagnosis and the incidence of this complication. JOP. 2002;3:195-201.
18. Skude G, Wehlin L, Maruyama T, Ariyama J. Hyperamylasemia after duodenoscopy and retrograde cholangiopancreatography. Gut. 1976;17:127-32.
19. La Ferla G, Gordon S, Archibald M, Murria WR. Hyperamylasemia and acute pancreatitis following endoscopic retrograde cholangiopancreatography. Pancreas. 1986;1:60-3.
20. Hamilton I, Lintott DJ, Rothwell J, Axon ATR. Acute pancreatitis following endoscopic retrograde cholangiopancreatography. Clin Radiol. 1983;34:543-6.
21. Skamene A, Patel YC. Infusion of graded concentrations of somatostatin in man: pharmacokinetics and differential inhibitory effects on pituitary and islet hormones Clin Endocrinol (Oxf). 1984;20:555-64.
22. Clements D, Rhodes JM, Elias E. Effect of somatostatin on oesophageal variceal pressure assessed by direct measurement. J Hepatol. 1986;2:262-6.
23. Loperfido S, Angelini G, Benedetti G, Chivoli F, Costan F, De Berrardinis F, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc. 1998;48:1-10.
24. Haber GB. Prevention of post-ERCP pancreatitis. Gastrointest Endosc. 2000;51:100-3.
25. Kozarek RA. ERCP economics. Gastrointest Endosc. 1999;49:660-2.
26. Borda F, Jiménez FJ, Vila J, Carral D, Zozaya JM, Pastor G, et al. Estudio coste-efectividad del empleo de somatostatina para la disminución de pancreatitis agudas post-CPRE. Gastroenterol Hepatol. 2001;24:292-6.
27. Gotzsche PC, Hrobjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database Syst Rev. 2005;1:CD000193.
28. Trap P, Adamsen S, Har-Hansen O, Henriksen M. Severe and fatal complications after therapeutic ERCP: a prospective series of claims to insurance covering public hospitals. Endoscopy. 1999;31:125-30.